Related Experiment Video
Updated: May 18, 2026
04:22
Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
Published on: May 30, 2025
Trazodone in methandone induced erectile dysfunction.
Faezeh Tatari1, Vahid Farnia, Reza Faghih Nasiri
1Behavioral Sciences Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Iranian Journal of Psychiatry
|September 7, 2012
Summary
Trazodone treatment showed potential in improving erectile dysfunction (ED) for men undergoing Methadone Maintenance Therapy (MMT). Further research is needed to confirm these findings in larger, controlled studies.
Area of Science:
- Urology
- Psychiatry
- Pharmacology
Background:
- Men undergoing Methadone Maintenance Therapy (MMT) exhibit a high prevalence of Erectile Dysfunction (ED).
- ED in this population is often linked to hypogonadism and depression.
- Existing treatments for ED in MMT patients require further investigation.
Purpose of the Study:
- To evaluate the efficacy of Trazodone, an antidepressant with known effects on sexual function, in treating ED among men on MMT.
Main Methods:
- A cohort of 157 men on MMT were interviewed regarding demographics, drug use, and sexual behavior.
- Erectile function was assessed using the Erectile Dysfunction (ED) Intensity Scale.
- 75 patients received Trazodone (50mg initially, then 100mg for 6 weeks); 55 completed the study.
Main Results:
- The prevalence of ED in the sample was 60.5%.
- The mean ED Intensity Scale score significantly improved from 12.21 before treatment to 16.78 after Trazodone treatment (P<0.05).
- ED severity was significantly correlated with the duration and daily dosage of Methadone therapy.
Conclusions:
- Trazodone demonstrates potential efficacy in managing methadone-induced Erectile Dysfunction.
- Larger, controlled studies are recommended to validate these preliminary findings.
- Trazodone may offer a therapeutic option for sexual dysfunction in men on MMT.
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...